T cells with BsAb required stronger pulling forces to detach from the tumor cells when compared with the two controls (Figure 6).
Future cell avidity analyses of engineered BsAb, will enable researchers to discover and fine-tune optimal antibodies for T cell therapies.
6 Left: Avidity curve representing the average proportion of bound T cells (BsAb-engaged or control conditions) upon an applied force ramp. Right: Bar graph representing percentage of target-bound T cells at the minimal force (based on no BsAb negative control-detachment) as gated from the avidity curve. (rForce indicates relative force).